Announcements and Notices - [Connected Transaction]

Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.

Termination Of Connected Transaction

Announcements and Notices - [Inside Information]

Inside Information Announcement - Update On The Company'S Product Revenue In The Third Quarter Of 2024

Connected Transaction - Proposed Subscription And Deemed Disposal Of Equity Interest In A Subsidiary

Financial Statements/ESG Information - [Interim/Half-Year Report]

2024 Interim Report

Announcements and Notices - [Other - Business Update]

Voluntary Announcement -
The National Medical Products Administration
Accepted The New Drug Application For Picankibart For
Moderate To Severe Plaque Psoriasis

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Termination Of Connected Transaction

Inside Information Announcement - Update On The Company'S Product Revenue In The Third Quarter Of 2024

Connected Transaction - Proposed Subscription And Deemed Disposal Of Equity Interest In A Subsidiary

2024 Interim Report

Voluntary Announcement - The National Medical Products Administration Accepted The New Drug Application For Picankibart For Moderate To Severe Plaque Psoriasis